Indirect cost-effectiveness analyses of abatacept and rituximab in patients with moderate-to-severe rheumatoid arthritis in the United States. [electronic resource]
Producer: 20110428Description: 33-41 p. digitalISSN:- 1941-837X
- Abatacept
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal, Murine-Derived -- economics
- Antirheumatic Agents -- economics
- Cost-Benefit Analysis
- Disability Evaluation
- Female
- Health Status Indicators
- Humans
- Immunoconjugates -- economics
- Immunologic Factors -- economics
- Methotrexate -- economics
- Middle Aged
- Monte Carlo Method
- Quality-Adjusted Life Years
- Rheumatic Fever -- drug therapy
- Rituximab
- Severity of Illness Index
- Surveys and Questionnaires
- Tumor Necrosis Factor-alpha -- antagonists & inhibitors
- United States
- Young Adult
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.